文献速递妇科

IIIC期子宫内膜样与非子宫内膜样子宫内膜癌的辅助联合模式治疗

Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2019-05-17

本回顾性研究纳入本机构1985至2015年接受手术分期的249例FIGO 2009 IIIC期子宫内膜癌患者,比较辅助放疗、化疗或放化疗联合的生存结局。结果显示,联合模式治疗(含盆腔外照射放疗)对淋巴结阳性各亚型均带来良好结局,非子宫内膜样癌从辅助放化疗中获得的疾病特异性生存获益最明显。

要点

  • 全部患者5年疾病特异性生存率为65%。
  • 3级子宫内膜样癌中,放化疗联合较单纯化疗5年疾病特异性生存更高(61% vs 27%,P=0.04)。
  • 非子宫内膜样癌中,同步放化疗后序贯化疗较单纯同步放化疗5年疾病特异性生存更高(74% vs 50%,P=0.02)。

核心结论

  • 含辅助盆腔外照射放疗的联合模式治疗使淋巴结阳性子宫内膜癌各亚型均获得良好结局。
  • 辅助放化疗的疾病特异性生存优势在非子宫内膜样子宫内膜癌女性中最为明显。

研究设计与样本

  • 回顾性识别本机构1985至2015年接受手术分期的249例FIGO 2009 IIIC期子宫内膜癌女性。
  • 患者术后接受外照射放疗、化疗或化疗联合放疗。
  • 生存率采用Kaplan-Meier法计算。

主要发现

  • 全部患者5年疾病特异性生存率为65%。
  • 3级子宫内膜样癌中,辅助放化疗联合较单纯化疗5年疾病特异性生存率更高(61% vs 27%,P=0.04)。
  • 非子宫内膜样癌中,辅助放化疗联合较单纯化疗5年疾病特异性生存率更高(67% vs 38%,P=0.02)。
  • 非子宫内膜样癌中,同步放化疗后追加序贯化疗较单纯同步放化疗5年疾病特异性生存率更高(74% vs 50%,P=0.02)。
  • 全部患者中,3年盆腔复发率放疗±化疗为5%,单纯化疗为35%(P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify the optimal adjuvant treatment regimen for patients with endometrioid and non-endometrioid node-positive endometrial cancer. METHODS: We retrospectively identified 249 women with FIGO 2009 stage IIIC endometrial cancer at our institution who underwent surgical staging from 1985 to 2015 followed by external beam radiotherapy (RT), chemotherapy (CT), or a combination of CT + RT. Survival rates were calculated using the Kaplan-Meier method. RESULTS: The 5-year disease-specific survival (DSS) rate for all patients was 65%. Adjuvant CT + RT conferred higher rates of 5-year DSS as compared to CT alone in patients with grade 3 endometrioid and non-endometrioid tumors (61% vs. 27%, P = 0.04 and 67% vs. 38%, P = 0.02, respectively). Among patients with non-endometrioid tumors, treatment with concurrent chemoradiotherapy followed by additional sequential chemotherapy had higher 5-year DSS rates than with concurrent chemoradiotherapy alone (74% vs. 50%, P = 0.02). The 3-year pelvic recurrence rate was 5% with RT ± CT and 35% with CT alone (P < 0.001) for all patients. No paraaortic nodal failures were observed following extended-field RT, but 14% of patients who received pelvic-only RT or CT alone developed recurrences in the paraaortic nodes (P < 0.001). CONCLUSIONS: Combined-modality therapy including adjuvant external beam pelvic radiotherapy yields excellent outcomes for patients with all subtypes of node-positive endometrial cancer. The most pronounced DSS advantage from adjuvant chemoradiotherapy was evident in women with non-endometrioid endometrial cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chapman BV, Swanick CW, Ning MS, et al. Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. Gynecol Oncol. 2019. PMID: 31109659. doi:10.1016/j.ygyno.2019.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。